


**K**  : Eye transplantation; Ophthalmology; Immunosuppression

**Citation:**

... a egie , ca e ... d ... de ail , and o ... come , ... e e ... ac ed f om  
elec ed ... die . Da a e ... ac ion ... a pe fo med independen ... b ...  
m l ip le e ie ... o en ... e acc ... ac and eliabili ...

**S**

E ... ac ed da a e e ... n he ized op o idea ... c ... ed na ... a i e on  
... he hi ... o ical e ol ... ion of ese ... an plan a ion , ca ego ized b ... o gical  
app oache , imm ... nological challenge , and e hical con ide a ion .  
Compa a i e anal ... e of ... a io ... die and ad ancemen ... e e

feasibility and success of these an plan a ion.

**S a a a**

Advancement in logical precision and the integration of cutting-edge technologies emerged a key theme. The evolution from traditional corneal grafts to advanced procedures like DMEK underscored the importance of precision in achieving favorable outcomes. Corneal endothelial transplantation (A) advanced dissection completed the advancement in corneal transplantation with the emergence of endothelial transplantation. While corneal procedures have been a substantial achievement, challenges in endothelial transplantation, such as operative technique and immune modulation, were identified as areas requiring further investigation.

**I**

These interdisciplinary advancements in immunoprophylaxis strategies, emphasizing a holistic approach to tailored and personalized approaches, are pivotal in minimizing the risk of rejection while reducing the burden of long-term immunosuppression.

**G a a a**

Strengthening data on graft survival and visual outcomes provided a comprehensive understanding of the progress in the field. Improved outcomes suggest that enhanced surgical techniques and immunoprophylaxis are pivotal in impacting patient experience and visual rehabilitation.

**E a a**

Ethical considerations are critically discussed, recognizing the importance of ethical frameworks guiding advancement. The potential for transplant communication, informed consent, and ethical clinical trials

(ce.1( ia11 Tf0. m(p)-9(o3(l o(n ))ce o)123.1(e)-)8(g a)13(e)0.enn 1-6(a)9(n)

**Citation:**

6. Tanhehco YC, Weisberg S, Schwartz J (2016) Pancreatic islet autotransplantation for nonmalignant and malignant indications. *Transfusion* 56: 761-770.
7. Balzano G, Ma f P, Nano R, Mercalli A, Melzi R, et al. (2016) Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis. *Am J Transplant* 16:1812-1826.
8. Muratore S, Zeng X, Korc M, McElyea S, Wilhelm J, et al. (2016) Metastatic Pancreatic Adenocarcinoma After Total Pancreatectomy Islet Autotransplantation for Chronic Pancreatitis. *Am J Transplant* 16: 2747-2752.
9. Siegel M, Barlowe T, Smith KD, Chaidarun SS, LaBarre N, et al. (2020) Islet autotransplantation improves glycemic control in patients undergoing elective distal pancreatectomy for benign inflammatory disease. *Clin Transplant* 34: 13891.
10. Jin SM, Oh SH, Kim SK, Jung HS, Choi SH, et al. (2013) Diabetes-free survival in patients who underwent islet autotransplantation after 50% to 60% distal partial pancreatectomy for benign pancreatic tumors. *Transplantation* 95: 1396-403.